Company Overview
About ROME Therapeutics
ROME Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company pioneering a novel approach to drug discovery by targeting the "dark genome" — the vast portion of the human genome composed of repetitive DNA sequences that has historically been ignored or considered non-functional. ROME''s scientific hypothesis is that specific classes of genomic repeats, particularly LINE-1 (Long Interspersed Nuclear Elements) retrotransposons, become aberrantly activated in diseased cells — including cancer cells and cells involved in autoimmune disorders — and drive disease pathology through mechanisms distinct from traditional drug targets.
Business Model & Competitive Advantage
ROME has attracted nearly $200 million in total funding, including a $149 million Series B that saw rare pharma strategic investment: Johnson & Johnson, Bristol Myers Squibb, Sanofi, Eurofarma Ventures, Mirae Asset Capital, Luma Group, and ARCH Venture Partners all participated. This strategic investor consortium reflects the pharmaceutical industry''s growing conviction that dark genome biology represents a major untapped therapeutic opportunity. ROME''s lead program is a small-molecule inhibitor of LINE-1 reverse transcriptase, targeting the enzyme these retrotransposons use to proliferate in disease states. This program is advancing toward first-in-human trials as a treatment for lupus and other interferon-driven autoimmune diseases.
Competitive Landscape 2025–2026
In late 2025, ROME refocused its pipeline on autoimmune and neurodegenerative diseases, deprioritizing certain oncology programs, and made staff reductions to extend its financial runway through clinical proof-of-concept. The company continues to co-host the annual Dark Genome Symposium with Enara Bio, positioning itself as the scientific hub for an emerging field that multiple large pharmaceutical companies are beginning to explore.
Key Differentiators
Strong Challenger
ROME Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare ROME Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ROME Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ROME Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ROME Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →